2-Fluorodeschloroketamine - Clearmind Medicine
Alternative Names: 2-FDCKLatest Information Update: 02 Feb 2023
At a glance
- Originator Clearmind Medicine
- Developer Bar-Ilan University; Clearmind Medicine
- Class Antidepressants; Cyclohexanones; Fluorine compounds; Small molecules
- Mechanism of Action NMDA receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Major depressive disorder
Most Recent Events
- 31 Jan 2023 Clearmind Medicine has patent pending for the use of 2-Fluorodeschloroketamine in treating depression in USA
- 31 Jan 2023 Preclinical trials in Major depressive disorder in Canada (unspecified route) before January 2023
- 31 Jan 2023 Pharmacodynamics data from a preclinical trial in Major depressive disorder released by Clearmind Medicine